Bopindolol: pharmacological basis and clinical implications.
Bopindolol, a non-selective antagonist of beta 1- and beta 2-adrenoceptors (ARs), has been found by pharmacological, molecular biological techniques and molecular modeling to have several unique properties. Bopindolol produces sustained blockade of beta 1- and beta 2-ARs, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Also, our recent molecular modeling studies identified possible interaction sites between bopindolol and beta-AR subtypes. The reviewed studies support our findings that bopindolol is non-selective for beta 1- and beta 2-ARs, has low affinity for beta 3-AR subtype and has pharmacological properties that are likely to be beneficial in the treatment of cardiovascular diseases.
Nagatomo
T
T
Department of Pharmacology, Niigata College of Pharmacy, 5-13-2 Kamishinei-cho, Niigata 950-2081, Japan. nagatomo@niigata-pharm.ac.jp
Hosohata
Y
Y
Ohnuki
T
T
Nakamura
T
T
Hattori
K
K
Suzuki
J
J
Ishiguro
M
M
D000319:Adrenergic beta-Antagonists / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004195:Disease Models, Animal; D006439:Hemodynamics / Q000187:drug effects; D008958:Models, Molecular; D009200:Myocardial Contraction / Q000187:drug effects; D010869:Pindolol / Q000031:analogs & derivatives / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011943:Receptors, Adrenergic, beta / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D012083:Renin / Q000378:metabolism; D000092502:Renin Inhibitors
D000319:Adrenergic beta-Antagonists; D010869:Pindolol; D011943:Receptors, Adrenergic, beta; D011985:Receptors, Serotonin; D012083:Renin; D000092502:Renin Inhibitors; C036007:bopindolol